RSCI vs TAK
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RSCI is a Hold and TAK is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RSCI’s FA Score shows that 1 FA rating(s) are green whileTAK’s FA Score has 1 green FA rating(s).
- RSCI’s FA Score: 1 green, 4 red.
- TAK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
TAK’s TA Score shows that 4 TA indicator(s) are bullish.
- TAK’s TA Score: 4 bullish, 4 bearish.
Price Growth
RSCI (@Pharmaceuticals: Other) experienced а +14.24% price change this week, while TAK (@Pharmaceuticals: Other) price change was -2.09% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -5.01%. For the same industry, the average monthly price growth was -7.82%, and the average quarterly price growth was -7.80%.
Reported Earning Dates
TAK is expected to report earnings on Jan 30, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (-5.01% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| RSCI | TAK | RSCI / TAK | |
| Capitalization | N/A | 43.1B | - |
| EBITDA | N/A | 1.01T | - |
| Gain YTD | 115.932 | -2.934 | -3,951% |
| P/E Ratio | N/A | 36.79 | - |
| Revenue | N/A | 4.17T | - |
| Total Cash | N/A | 317B | - |
| Total Debt | N/A | 4.66T | - |
RSCI | TAK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 34 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 33 Fair valued | 19 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 83 | |
PRICE GROWTH RATING 1..100 | 93 | 59 | |
P/E GROWTH RATING 1..100 | 100 | 89 | |
SEASONALITY SCORE 1..100 | n/a | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TAK's Valuation (19) in the Pharmaceuticals Major industry is in the same range as RSCI (33) in the null industry. This means that TAK’s stock grew similarly to RSCI’s over the last 12 months.
TAK's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as RSCI (100) in the null industry. This means that TAK’s stock grew similarly to RSCI’s over the last 12 months.
TAK's SMR Rating (83) in the Pharmaceuticals Major industry is in the same range as RSCI (100) in the null industry. This means that TAK’s stock grew similarly to RSCI’s over the last 12 months.
TAK's Price Growth Rating (59) in the Pharmaceuticals Major industry is somewhat better than the same rating for RSCI (93) in the null industry. This means that TAK’s stock grew somewhat faster than RSCI’s over the last 12 months.
TAK's P/E Growth Rating (89) in the Pharmaceuticals Major industry is in the same range as RSCI (100) in the null industry. This means that TAK’s stock grew similarly to RSCI’s over the last 12 months.
| TAK | |
|---|---|
| RSI ODDS (%) | 2 days ago 50% |
| Stochastic ODDS (%) | 2 days ago 44% |
| Momentum ODDS (%) | 2 days ago 57% |
| MACD ODDS (%) | 2 days ago 48% |
| TrendWeek ODDS (%) | 2 days ago 50% |
| TrendMonth ODDS (%) | 2 days ago 43% |
| Advances ODDS (%) | 2 days ago 44% |
| Declines ODDS (%) | 4 days ago 44% |
| BollingerBands ODDS (%) | 2 days ago 43% |
| Aroon ODDS (%) | 2 days ago 44% |
RSCI and
Correlation & Price change
A.I.dvisor tells us that RSCI and TAK have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RSCI and TAK's prices will move in lockstep.
| Ticker / NAME | Correlation To RSCI | 1D Price Change % | ||
|---|---|---|---|---|
| RSCI | 100% | N/A | ||
| TAK - RSCI | 24% Poorly correlated | +0.07% | ||
| ETST - RSCI | 22% Poorly correlated | -4.08% | ||
| TEVJF - RSCI | 5% Poorly correlated | +10.33% | ||
| ROMJF - RSCI | 5% Poorly correlated | +12.43% | ||
| PCYN - RSCI | 4% Poorly correlated | N/A | ||
More | ||||
TAK and
Correlation & Price change
A.I.dvisor tells us that TAK and ELAN have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TAK and ELAN's prices will move in lockstep.
| Ticker / NAME | Correlation To TAK | 1D Price Change % | ||
|---|---|---|---|---|
| TAK | 100% | +0.07% | ||
| ELAN - TAK | 27% Poorly correlated | -1.06% | ||
| RDY - TAK | 25% Poorly correlated | -2.20% | ||
| ZTS - TAK | 24% Poorly correlated | -1.36% | ||
| SNOA - TAK | 24% Poorly correlated | -1.15% | ||
| CRON - TAK | 23% Poorly correlated | -4.61% | ||
More | ||||